MTNB

$0.64

Post-MarketAs of Mar 17, 7:53 PM UTC

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Insider Monkey
Sep 23, 2025

Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Matinas BioPharma Holdings, Inc. is one of them. Matinas BioPharma Holdings, Inc. (NYSE:MTNB) is a clinical-stage biopharmaceutical company developing oral anti-infective therapies using its proprietary lipid nanocrystal (LNC) platform. Its lead candidate, MAT2203, an […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.